<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850265</url>
  </required_header>
  <id_info>
    <org_study_id>FORM-DPB-extrafine</org_study_id>
    <nct_id>NCT00850265</nct_id>
  </id_info>
  <brief_title>Effect of Spacer in Extrafine Formoterol-Beclomethasone Treatment to Asthma</brief_title>
  <official_title>Rol of Spacer in the Combined Treatment With Extrafine Beclomethasone-Formoterol in Stable Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Requena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Requena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined inhaled treatment with long acting adrenergics and steroids in an unique inhaler&#xD;
      plays an important role in the management of non-mild asthma. Some studies have demonstrated&#xD;
      that the use of spacers achieve better lung deposition and decrease the number of side&#xD;
      effects. Recently a new combined treatment for asthma has been developed (extrafine&#xD;
      formoterol plus beclomethasone dipropionate). The small size of the extrafine particles of&#xD;
      this new combination get the small airway and theorically improve their positive effect. Some&#xD;
      authors have stated that the use of a spacer with extrafine particle could decrease the&#xD;
      effectiveness of this treatment due to the adhesion of particles on the walls of the spacer&#xD;
      because of the electrostatic characteristics of plastic spacers. However, there are no&#xD;
      clinical or functional studies demonstrating the role of this phenomena in the control of&#xD;
      asthmatic patients. The investigators' hypothesis is that the benefit of using spacers with&#xD;
      this new treatment is at least equal in magnitude than the loss of efficacy because of the&#xD;
      adhesion of particles on the wall of the spacer and then the investigators hypothesized that&#xD;
      the use of spacer with extrafine formoterol-beclomethasone do not suppose a decrease in&#xD;
      clinical or functional control in stable moderate-severe asthma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Questionnaire</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Flow</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthmatics Symptoms</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhalation technique</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extrafine formoterol plus beclomethasone with spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Spacer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Extrafine formoterol plus beclomethasone without spacer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Volumatic spacer</intervention_name>
    <description>A spacer is a plastic device to inhaler medication</description>
    <arm_group_label>Spacer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate-severe asthma&#xD;
&#xD;
          -  Stable asthma&#xD;
&#xD;
          -  18-75 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exacerbation of asthma&#xD;
&#xD;
          -  Instability with the study treatment&#xD;
&#xD;
          -  Other cardiopulmonary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Requena</name>
      <address>
        <city>Requena-Valencia</city>
        <state>Valencia</state>
        <zip>46340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>March 26, 2009</last_update_submitted>
  <last_update_submitted_qc>March 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Miguel Angel Martínez García</name_title>
    <organization>Hospital General de Requena</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Formoterol</keyword>
  <keyword>Beclomethasone</keyword>
  <keyword>Extrafine formulation</keyword>
  <keyword>Spacer</keyword>
  <keyword>Moderate</keyword>
  <keyword>Severe</keyword>
  <keyword>Stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

